Glenmark Stock - analyst consensus and valuation snapshot
21.06.2026 - 22:38:15 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 20:36 UTC. Details in the imprint.
Glenmark Pharmaceuticals (INE935A01035) is drawing steady interest from domestic brokerages even without fresh corporate headlines. A range of India-based analysts currently publish target prices and scenario analyses for the stock, providing a structured view of upside and risk according to recent aggregation data.
All news and key data on Glenmark Pharmaceuticals stock
Further regulatory filings, quarterly releases and price data on Glenmark Pharmaceuticals can be found in the dedicated topic section and on the company’s investor relations site.
What the analyst data shows
Recent consensus summaries compiled by regional broker aggregators indicate average 12-month target prices for Glenmark Pharmaceuticals stock in a corridor between roughly INR 1,850 and INR 1,920 per share, implying a double-digit percentage upside from current trading levels according to one such overview. Analyst compilation on Bitget
Within this range, more cautious domestic houses cluster around approximately INR 1,600 on regulatory and margin concerns, while more bullish forecasts extend toward INR 2,100 where analysts model faster US business expansion and improved plant utilization. Bitget summary of bull and bear cases
Background on valuation and positioning
Glenmark Pharmaceuticals focuses on generics and branded formulations in therapies such as dermatology, respiratory and oncology, alongside a growing presence in active pharmaceutical ingredients. The group also pursues specialty and innovative molecules, aiming to balance stable cash flows and selective higher-margin products. Company profile on Glenmark
The analyst spread around the current consensus corridor reflects this mix: predictable generic volumes in regulated markets, offset by pricing pressure, compliance costs and periodic regulatory inspections that can influence earnings trajectories.
How the company makes money
Glenmark Pharmaceuticals generates most of its revenue from selling generic and branded prescription medicines across India, the United States and other international markets, with key lines in respiratory inhalers, dermatology treatments and oncology drugs plus supporting active pharmaceutical ingredients.
Where the stock trades today
The shares of Glenmark Pharmaceuticals (INE935A01035) trade on the National Stock Exchange of India and BSE; the latest reliably available quote before publication was in Indian rupees on these domestic venues.
Key facts on Glenmark Pharmaceuticals stock
- Company: Glenmark Pharmaceuticals Ltd.
- ISIN: INE935A01035
- WKN: A0DKQ3
- Ticker: GLENMARK
- Venue: NSE / BSE (India)
- Price (as of last reliable quote): data in INR on Indian exchanges
- Market cap: latest figure based on domestic trading in Indian rupees
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: represented in Indian sectoral and mid-cap indices where applicable
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
